Literature DB >> 27189222

TFE3-Expressing Perivascular Epithelioid Cell Neoplasm (PEComa) of the Sella Turcica.

Martin D Hyrcza1,2, Daniel A Winer1,2,3, Mary Shago2,4, Karolyn Au5, Gelareh Zadeh3,5, Sylvia L Asa1,2,3, Ozgur Mete6,7,8.   

Abstract

We report a primary central nervous system (CNS) perivascular epithelioid cell tumor (PEComa) in a middle-aged female patient. The tumor occurred in suprasellar location with secondary extension into the sella turcica. The patient presented with intracranial hemorrhage and an altered level of consciousness. The tumor had morphologic features matching those of other previously described TFE3-translocated PEComas, including epithelioid morphology, diffuse and strong nuclear immunoreactivity for TFE3, and minimal staining with myoid markers. The TFE3 break-apart FISH testing showed a slight splitting of one of the TFE3 signals in 49.5 % of nuclei. This case illustrates that PEComas should be added to the growing list of mesenchymal tumors that can be encountered in the CNS and specifically in the vicinity of the pituitary gland. The recognition of this entity is of significance given their underlying pathogenesis and possible management implications.

Entities:  

Keywords:  FISH; Nonfunctioning sellar mass; PEComa; Pituitary adenoma; TFE3

Mesh:

Substances:

Year:  2017        PMID: 27189222     DOI: 10.1007/s12022-016-9434-7

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  18 in total

Review 1.  Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature.

Authors:  Andrew L Folpe; Thomas Mentzel; Hans-Anton Lehr; Cyril Fisher; Bonnie L Balzer; Sharon W Weiss
Journal:  Am J Surg Pathol       Date:  2005-12       Impact factor: 6.394

2.  A distinctive subset of PEComas harbors TFE3 gene fusions.

Authors:  Pedram Argani; Sebastian Aulmann; Peter B Illei; George J Netto; Jae Ro; Hyun-yee Cho; Snjezana Dogan; Marc Ladanyi; Guido Martignoni; John R Goldblum; Sharon W Weiss
Journal:  Am J Surg Pathol       Date:  2010-10       Impact factor: 6.394

3.  TTF-1 expressing sellar neoplasm with ependymal rosettes and oncocytic change: mixed ependymal and oncocytic variant pituicytoma.

Authors:  Zaid Saeed Kamil; Grant Sinson; Hasan Gucer; Sylvia L Asa; Ozgur Mete
Journal:  Endocr Pathol       Date:  2014-12       Impact factor: 3.943

4.  Perivascular epithelioid cell tumor of the nasal cavity with TFE3 expression.

Authors:  Naoto Kuroda; Masakazu Goda; Dmitry V Kazakov; Ondrej Hes; Michal Michal; Gang-Hong Lee
Journal:  Pathol Int       Date:  2009-10       Impact factor: 2.534

5.  Sellar glomangioma.

Authors:  Julius O Ebinu; Mehdi Shahideh; George M Ibrahim; Allan Vescan; Fred Gentili; Rowena Ridout; Sylvia Asa; Gelareh Zadeh
Journal:  Endocr Pathol       Date:  2011-12       Impact factor: 3.943

6.  TFE3 translocation-associated perivascular epithelioid cell neoplasm (PEComa) of the gynecologic tract: morphology, immunophenotype, differential diagnosis.

Authors:  J Kenneth Schoolmeester; Linda N Dao; William R Sukov; Lu Wang; Kay J Park; Rajmohan Murali; Meera R Hameed; Robert A Soslow
Journal:  Am J Surg Pathol       Date:  2015-03       Impact factor: 6.394

Review 7.  Alveolar soft-part sarcoma: a review and update.

Authors:  A L Folpe; A T Deyrup
Journal:  J Clin Pathol       Date:  2006-11       Impact factor: 3.411

8.  PEComa: another member of the MiT tumor family?

Authors:  Alberto Righi; Kypros Dimosthenous; Juan Rosai
Journal:  Int J Surg Pathol       Date:  2008-01       Impact factor: 1.271

9.  Xp11 neoplasm with melanocytic differentiation of the prostate harbouring the novel NONO-TFE3 gene fusion: report of a unique case expanding the gene fusion spectrum.

Authors:  Xiao-Tong Wang; Qiu-Yuan Xia; Hao Ni; Zi-Yu Wang; Sheng-Bing Ye; Rui Li; Xuan Wang; Jing-Huan Lv; Shan-Shan Shi; Heng-Hui Ma; Zhen-Feng Lu; Qin Shen; Xiao-Jun Zhou; Qiu Rao
Journal:  Histopathology       Date:  2016-03-31       Impact factor: 5.087

10.  "Malignant" perivascular epithelioid cell neoplasm: risk stratification and treatment strategies.

Authors:  Jonathan S Bleeker; J Fernando Quevedo; Andrew L Folpe
Journal:  Sarcoma       Date:  2012-04-26
View more
  6 in total

Review 1.  Immunohistochemical Biomarkers in Pituitary Pathology.

Authors:  Sylvia L Asa; Ozgur Mete
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

2.  Uterine PEComas: A Morphologic, Immunohistochemical, and Molecular Analysis of 32 Tumors.

Authors:  Jennifer A Bennett; Ana C Braga; Andre Pinto; Koen Van de Vijver; Kristine Cornejo; Anna Pesci; Lei Zhang; Vicente Morales-Oyarvide; Takako Kiyokawa; Gian Franco Zannoni; Joseph Carlson; Tomas Slavik; Carmen Tornos; Cristina R Antonescu; Esther Oliva
Journal:  Am J Surg Pathol       Date:  2018-10       Impact factor: 6.394

Review 3.  Immunohistochemical Biomarkers of Mesenchymal Neoplasms in Endocrine Organs: Diagnostic Pitfalls and Recent Discoveries.

Authors:  Yin P Hung; Jason L Hornick
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

4.  Malignant perivascular epithelioid cell tumor mimicking jugular foramen schwannoma: A case report and literature review.

Authors:  Noritaka Komune; Shogo Masuda; Ryuji Yasumatsu; Takahiro Hongo; Rina Jiromaru; Satoshi Matsuo; Osamu Akiyama; Nana Tsuchihashi; Nozomu Matsumoto; Hidetaka Yamamoto; Takashi Nakagawa
Journal:  Heliyon       Date:  2020-01-17

5.  An Inguinal Perivascular Epithelioid Cell Tumor Metastatic to the Orbit.

Authors:  Zofia Tynski; Way Chiang; Albert Barrett
Journal:  Case Rep Pathol       Date:  2018-05-29

6.  Primary glomus tumour of the pituitary gland: diagnostic challenges of a rare and potentially aggressive neoplasm.

Authors:  Boon Leong Quah; Carmine Antonio Donofrio; Stefano La Rosa; Jean-Philippe Brouland; Giulia Cossu; Ibrahim Djoukhadar; Helen Mayers; Patrick Shenjere; Marta Pereira; Omar N Pathmanaban; Muhammed O Murtaza; Rao Gattamaneni; Federico Roncaroli; Konstantina Karabatsou
Journal:  Virchows Arch       Date:  2020-09-12       Impact factor: 4.064

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.